Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Yesterday's post-US-election review was more positive, but I came across some good stuff that I did not have the time to cover yesterday. So here are the rest. And it might not be all good news. Recen ...

Breeders’ rights have been officially granted for Pinpu black swine and Yuansing cattle, marking a milestone in ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

after analysts at JPMorgan Chase & Co. predicted the Danish biotech firm’s experimental weight-loss drug petrelintide could ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

STAT's Readout LOUD podcast discusses how Trump's second term and the MAHA movement could affect FDA regulation, the ...

The firm had received notice last year that it was out of compliance with a requirement to maintain a minimum $15 million market value of publicly held shares.

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...